Get the Stockscreener App
184.25
3.46%
-6.605
After Hours:
184.21
-0.04
-0.02%
Praxis Precision Medicines Inc stock is traded at $184.25, with a volume of 720.11K.
It is down -3.46% in the last 24 hours and up +5.91% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$190.85
Open:
$191.59
24h Volume:
720.11K
Relative Volume:
0.82
Market Cap:
$4.61B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-20.09
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+0.07%
1M Performance:
+5.91%
6M Performance:
+390.68%
1Y Performance:
+146.72%
1-Day Range:
$183.55
$192.29
1-Week Range:
$160.11
$197.50
52-Week Range:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
184.25 | 4.77B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
PRAX: HC Wainwright & Co. Reaffirms Buy Rating and Price Target - GuruFocus
Praxis Precision Medicines to Present Latest Epilepsy Pipeline Data at American Epilepsy Society Annual Meeting 2025 - Quiver Quantitative
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Praxis (NASDAQ: PRAX) to share epilepsy data at AES 2025 on vormatrigine and relutrigine - Stock Titan
Praxis Precision Medicines stock rating reiterated at Buy by TD Cowen - Investing.com UK
Praxis Precision Medicines Insider Sold Shares Worth $4,852,256, According to a Recent SEC Filing - MarketScreener
Praxis Precision Medicines Stock (PRAX) Opinions on Short Report Controversy - Quiver Quantitative
Praxis Precision Medicines exec sells $2.6m in shares By Investing.com - Investing.com South Africa
Praxis Precision Medicines general counsel sells $4.8m in shares By Investing.com - Investing.com Nigeria
[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity - Stock Titan
Praxis Precision Medicines general counsel sells $4.8m in shares - Investing.com
Praxis Precision Medicines exec sells $2.6m in shares - Investing.com
Praxis Precision Medicines Executives Engage in Significant Stock Transactions - TradingView
Officer Mastrocola Sells 13,600 ($2.6M) Of Praxis Precision Medicines Inc [PRAX] - TradingView
Is Praxis Precision Medicines Inc. stock near bottom after declineJuly 2025 Price Swings & Reliable Momentum Entry Alerts - newser.com
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) to Discuss Ulixacaltamide Data on Nov. 24 Call - Stock Titan
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' - Benzinga
Praxis Precision Medicine (PRAX) Stock Analysis Report | Financials & Insights - Benzinga
Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position - MSN
Praxis Precision Medicines (PRAX) Faces Challenges as Culper Res - GuruFocus
Officer Mastrocola Files To Sell 13,600 Of Praxis Precision Medicines Inc [PRAX] - TradingView
Praxis Precision Medicines drops after Culper Research short call (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines stock falls after Culper short report By Investing.com - Investing.com Canada
Culper Research says we are short Praxis Precision Medicines Inc - MarketScreener
Is Praxis Precision Medicines Inc. stock supported by strong fundamentalsWeekly Profit Report & Fast Gain Stock Tips - newser.com
Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN
How analysts rate Praxis Precision Medicines Inc. stock todayTrend Reversal & Accurate Intraday Trade Tips - newser.com
Is Praxis Precision Medicines Inc. stock a contrarian buyWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
BTIG Research Initiates Coverage on Praxis Precision Medicines With Buy Rating, $424 Price Target - MarketScreener
BTIG Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Using fundamentals and technicals on Praxis Precision Medicines Inc.July 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
BTIG Initiates Coverage on PRAX with Buy Rating and $424 Price T - GuruFocus
Published on: 2025-11-19 03:37:53 - newser.com
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Quarterly Investment Review & Daily Stock Trend Reports - newser.com
Commit To Purchase Praxis Precision Medicines At $100, Earn 27.5% Using Options - Nasdaq
Praxis Precision Medicines (PRAX) Price Target Increased by 11.27% to 287.79 - Nasdaq
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - MSN
What valuation multiples suggest for Praxis Precision Medicines Inc. stockIPO Watch & Entry Point Strategy Guides - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025. - MarketScreener
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):